Coadministration of lanreotide Autogel and pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone

Abstract

Evaluation of the efficacy and safety of coadministered lanreotide Autogel (120 mg/month) and pegvisomant (40-120 mg/week) in acromegaly. In patients partially controlled by somatostatin analogs, lanreotide Autogel plus pegvisomant normalized IGF 1 at a median effective pegvisomant dose of 60 mg/week in 78.9%.

In these patients, results suggest a pegvisomant-sparing effect versus daily pegvisomant monotherapy.

Keywords

• lanreotide Autogel
• pegvisomant
• acromegaly treatment
• IGF I normalisation